A 225-person tirzepatide trial in Japan has reported its metabolic detail, and one finding is unusually practical: across the treatment groups, the change in waist measurement tracked the change in visceral fat — the fat wrapped around the internal organs, and the kind that carries the metabolic risk — with a correlation of 0.84. Visceral fat is normally something you need a scan to see. In this trial, a tape measure came close to seeing it. Alongside that, inflammatory and liver-related blood markers moved substantially on the drug.
What SURMOUNT-J measured
SURMOUNT-J randomised Japanese adults with “obesity disease” and without diabetes, one-to-one-to-one, to tirzepatide 10 mg, tirzepatide 15 mg or placebo, each alongside lifestyle modification: 73 people at 10 mg, 77 at 15 mg and 75 on placebo, followed to week 72. Prespecified analyses covered obesity and glycaemic measures; post hoc analyses examined how changes in weight, body measurements, abdominal fat compartments and glucose handling related to one another.
The blood markers moved a long way. High molecular weight adiponectin — a hormone released by fat tissue that tends to rise as metabolic health improves — increased by a mean 78.9% at 10 mg and 88.4% at 15 mg, against 0.9% on placebo. Leptin fell 57.3% and 63.1%, against 8.4%. High-sensitivity C-reactive protein, a general inflammation marker, fell 55.1% and 65.3%, against 17.7%. Two liver-related markers fell as well: procollagen III by 21.3% and 24.8% (against 3.8%) and cytokeratin-18 by 59.8% and 62.0% (against 32.8%). All of those comparisons were reported at p < 0.001. Glucose, insulin and C-peptide measured across a 75-gram oral glucose tolerance test all fell significantly.
On the correlations, weight loss tracked visceral fat reduction at r = 0.72 to 0.84 depending on the group, and visceral fat reduction tracked waist measures at r = 0.84. A correlation of 1.0 would mean the two move in perfect lockstep and 0 would mean no relationship, so 0.84 is a tight fit. Weight and visceral fat reductions showed weaker, moderate correlations with the improvements in glucose, insulin and C-peptide, at r = 0.38 to 0.66 — related, but far from interchangeable.
Why the population matters
This trial was run entirely in Japan, and that is not incidental. Japan classifies “obesity disease” at a lower body-mass-index threshold than the United States does, and people of East Asian ancestry tend to carry more visceral fat at any given BMI. A trial in that population is therefore testing the drug in bodies that are, on average, lighter and more visceral-fat-heavy than the SURMOUNT-1 population most coverage of tirzepatide has been built on. The authors’ conclusion is framed accordingly: they say the strong link between waist and visceral fat supports using anthropometric measures as surrogate markers of visceral adiposity in Japanese patients with obesity disease, rather than as a universal rule.
The marker results fit what has been reported elsewhere for this class — inflammation down, adiponectin up, liver measures improving as visceral fat falls. What this analysis adds is the arithmetic linking them: in these participants, the more weight came off, the more visceral fat came off, and the more visceral fat came off, the more the glucose measures improved — though that last link was the loosest of the three.
What is not yet known
The correlation analyses were post hoc, meaning they were run after the data were in rather than planned in advance, which makes them hypothesis-generating rather than confirmatory. A correlation across a treated group also does not establish that shrinking visceral fat is what caused the metabolic markers to improve; weight, visceral fat and glucose handling all moved together under the same drug, and this design cannot separate them. Two hundred and twenty-five people is a modest trial, 72 weeks is not long enough to show whether any of these marker changes translate into fewer heart attacks or less liver disease, and the liver markers reported are blood proxies, not biopsies. Several of the authors are employees of Eli Lilly Japan, which makes tirzepatide and sponsored the trial. Whether the waist-to-visceral-fat relationship holds this tightly in other populations is exactly what the authors decline to claim.
Sources: Waki H, Kaneyuki E, Shingaki T, Oura T, Nagakubo T, Ishigaki Y. “Changes in Abdominal Adiposity and Associations With Metabolic Health Markers Following Tirzepatide in Japanese Participants With Obesity Disease: Results From the SURMOUNT-J Study.” Endocrine Practice, published online 19 September 2026. doi:10.1016/j.eprac.2026.09.006.
